دورية أكاديمية
Spanish registry of thrombotic thrombocytopenic purpura (REPTT): Data evidence and new developments
| العنوان: | Spanish registry of thrombotic thrombocytopenic purpura (REPTT): Data evidence and new developments |
|---|---|
| المؤلفون: | Mingot-Castellano, María Eva, Pascual-Izquierdo, Cristina, Río-Garma, Julio del |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2023 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Thrombotic thrombocytopenic purpura, Registry, Thrombotic microangiopathy, ADAMTS13, Complement system |
| الوصف: | Immuno Thrombotic thrombocytopenic purpura (iTTP) is a rare and potentially fatal disorder characterized by systemic microvascular thrombosis because of a severe deficiency of ADAMTS13. It is difficult to generate knowledge about TTP because of its low incidence and the lack of clinical trials. Most of the evidence on diagnosis, treatment, and prognosis has been generated from real-world data registries. In 2004, the Spanish Apheresis Group (GEA) implemented the Spanish registry of TTP (REPTT) with 438 patients suffering 684 acute episodes in 53 hospitals up to January 2022. REPTT has studied several aspects of TTP in Spain. The iTTP incidence in Spain our country is 2.67 (95 % CI 1.90–3.45) and the prevalence is 21.44 (95 % CI % 19.10–23.73) patients per million inhabitants. The refractoriness incidence is 4.8 % and exacerbation incidence was 8.4 %, with a median of follow-up of 131.5 months (IQR: 14–178 months). In a 2018 review, the mortality in the first episode due to TTP was 7.8 %. We have also found that de novo episodes require fewer PEX procedures than relapses. Since June 2023, REPTT will involve Spain and Portugal, with a recommended sampling protocol and new variables to improve the neurological, vascular and quality of life evaluation of these patients. The main strength of this project will be the involvement of a combined population of more than 57 million inhabitants, which implies an annual incidence of close to 180 acute episodes per year. This will allow us to provide better answers to questions like treatment efficacy, associated morbidity and mortality, and the possible neurocognitive and cardiac sequelae. ; Peer reviewed |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1473-0502 1878-1683 |
| العلاقة: | https://doi.org/10.1016/j.transci.2023.103725Test; No; Transfusion and Apheresis Science 62(3): 103725 (2023); http://hdl.handle.net/10261/353755Test |
| DOI: | 10.1016/j.transci.2023.103725 |
| الإتاحة: | https://doi.org/10.1016/j.transci.2023.103725Test http://hdl.handle.net/10261/353755Test |
| حقوق: | none |
| رقم الانضمام: | edsbas.87EBF8A1 |
| قاعدة البيانات: | BASE |
| تدمد: | 14730502 18781683 |
|---|---|
| DOI: | 10.1016/j.transci.2023.103725 |